Bioaegis Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
- Conditions
- Decompression Sickness
- Interventions
- Drug: Sodium Chloride 0.9% Inj pre-exposureDrug: Sodium Chloride 0.9% Inj post-exposureDrug: Recombinant human plasma gelsolin post-exposureDrug: Recombinant human plasma gelsolin pre-exposureOther: Hyperbaric chamber
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06216366
A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) CAUSED BY PNEUMONIA OR OTHER INFECTIONS
- Conditions
- Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other Infections
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Bioaegis Therapeutics Inc.
- Target Recruit Count
- 372
- Registration Number
- 2023-510109-16-00
- Locations
- 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Wellstar MCG Augusta University, Augusta, Georgia, United States
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
- Conditions
- HealthyVolunteers
- Interventions
- Other: placebo
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05789745
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
Rhu-pGSN for Severe Covid-19 Pneumonia
- Conditions
- Sars-CoV2
- Interventions
- Other: PlaceboDrug: Recombinant human plasma gelsolin (Rhu-pGSN)
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04358406
- Locations
- 🇷🇴
Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie, Timişoara, Romania
🇪🇸Sant Joan de Reus SAM University Hospital, Reus, Spain
🇪🇸Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
- Conditions
- Community-acquired Pneumonia
- Interventions
- Other: Normal Saline Placebo
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- BioAegis Therapeutics Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03466073
- Locations
- 🇦🇺
Cairns Hospital, Cairns, Queensland, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Footscray Hospital, Footscray, Victoria, Australia